Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Go back to Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study| Gilead Sciences (NASDAQ: GILD) | Delayed: 151.91 +0.54 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.37 | 52 Week High | $108.63 | |||
| Open | $151.10 | 52 Week Low | $71.39 | |||
| Day High | $152.98 | P/E | 83.93 | |||
| Day Low | $149.69 | EPS | $1.81 | |||
| Volume | 1,359,985 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 150.14 +2.06 (1.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.08 | 52 Week High | $65.46 | |||
| Open | $148.17 | 52 Week Low | $47.97 | |||
| Day High | $151.46 | P/E | 102.14 | |||
| Day Low | $148.00 | EPS | $1.47 | |||
| Volume | 1,246,437 | |||||
